Sam's Treatment Journey with OPZELURA® (ruxolitinib) cream 1.5%

Read below for Selected Safety Information.

See how a childhood friendship helped Sam find treatment for her nonsegmental vitiligo with OPZELURA® (ruxolitinib) cream 1.5%—a prescription topical treatment for nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended. It is not known if OPZELURA is safe and effective in children less than 12 years of age with atopic dermatitis or nonsegmental vitiligo. Individual results may vary.

This video is intended for informational use only, and is not designed to replace the medical advice of your healthcare provider. OPZELURA is a prescription medicine used on the skin (topical) for the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older.

Selected Safety Information

OPZELURA can cause serious side effects including serious infections, increased risk of death due to any reason, cancer and immune system problems, increased risk of major cardiovascular events, and blood clots.

OPZELURA can lower your ability to fight infections, including TB or hepatitis B or C. Serious lung infections, skin cancer, blood clots, and low blood cell counts occurred with OPZELURA. Before starting OPZELURA, tell your doctor if you have an infection, are being treated for one, have TB or have been in close contact with someone with TB; have or had hepatitis B or C. Your doctor should check for infections before and during treatment. Tell your doctor if you had blood clots in your legs or lungs. OPZELURA may cause low platelet, low red and white blood cell counts.

In people taking JAK inhibitors, serious infections, increased risk of death, lymphoma, other cancers, and major cardiovascular events have occurred. OPZELURA is a topical JAK inhibitor. People 50 and older with at least 1 heart disease risk factor have an increased risk of heart attack, stroke, blood clots, and death when taking JAK inhibitors by mouth. The most common side effects of OPZELURA in people treated for nonsegmental vitiligo include: acne at the application site, itching at the application site, common cold (nasopharyngitis), headache, urinary tract infection, redness at the application site, and fever.

Call your doctor for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at https://www.opzelura.com/vitiligo/#ISI .

Please see the Full Prescribing Information and Medication Guide at https://www.opzelura.com/prescribing-... which includes a more complete discussion of the risks associated with OPZELURA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to lncyte Medical Information at 1-855-463-3463.

Sponsored by lncyte Corporation. OPZELURA and the OPZELURA logo are registered trademarks of lncyte.

© 2024, Incyte.  MAT-OPZ-02181  04/24